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Leptin is one of adipocyte-secreted hormones. It signals to the brain and other tissues about the status of 
body energy reserves. Circulating leptin levels are directly proportional to the amount of the body fat. Leptin 
concentration increases when surfeit and decreases during fasting. Obese patients are hyperleptinemic compared 
with thin persons and they are tolerant to the central hypothalamic effects of leptin. The reduced sensitivity toward 
exogenous and endogenous leptin is commonly referred to as leptin resistance. Alterations in the signaling of 
the long isoform of the leptin receptor play the crucial role in leptin resistance. Surfeit may induce leptin resistance 
and other metabolic sequelae of obesity. Leptin insensitivity and insulin resistance play a major role in the 
development of type 2 diabetes. Metformin remains the preferred first-line pharmacologic agent for the treatment 
of type 2 diabetes. It reduces hepatic glucose production, increases glucose uptake in peripheral tissue and can 
lead to weight loss. Metformin decreases both insulin and leptin concentration, restores the sensitivity to these 
hormones. But some studies have shown poor relationship between metformin action and leptin level. And the 
mechanism of metformin action on leptin resistance remains unclear. Thus, these issues should be studied as 
well as polymorphisms in genes encoding metformin action.
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Leptin role in endocrine system
Adipose tissue is a complex, essential, and 
highly active metabolic and endocrine organ. 
It responds to afferent signals from traditional 
hormone systems and central nervous system 
but also expresses and secretes factors with 
important endocrine functions [1].  
The discovery of leptin in 1994 has changed 
the understanding of hormonal regulation of 
energy homeostasis and the role of adipose 
tissue from that of a depot storage organ to 
that of an active endocrine organ producing 
several bioactive peptides [2]. 
Leptin, a 167–amino acid peptide [Fig. 1], is 
one of the adipocyte-secreted hormones [1]. 
It is also expressed in other tissues, inclu-
ding placenta, mammary gland, testes, ovary, 
endometrium, stomach, hypothalamus, pitu-
itary, and others [3]. 
Leptin signals to brain and other tissues 
about the status of body energy reserves. Thus, 
that appropriate changes in food intake, energy 
expenditure, and nutrient partitioning can occur 
to maintain whole-body energy balance [4]. 
Circulating leptin levels are directly propor-
tional to the amount of the body fat [5] and 
fluctuate with acute changes in caloric intake 
[6]. Leptin concentration increases when surfeit 
and decreases during fasting [7].
Circulating leptin crosses blood brain bar-
rier and mediates its action through the Janus 
kinase (JAK)–signal transducer and activator of 
transcription (STAT) pathway (JAK–STAT3) [8].
Leptin exerts pleiotropic effects by binding 
and activating specific leptin receptors in the 
hypothalamus and other organs, has direct and 
indirect effects in metabolically active tissues, 
and regulates some neuroendocrine axes. Sev-
eral isoforms of the leptin receptor, resulting 
from alternative splicing, convey biological 
activity and are involved in mediating leptin's 
actions in brain and peripheral organs [2].
The long leptin receptor isoform (ObRb) is 
expressed particularly in hypothalamus, where 
it regulates energy homeostasis and neuroen-
docrine function [9]. In ventromedial hypo-
thalamus leptin stimulates expression of ano-
rexigenic brain-derived neurotrophic factor 
[10]. in addition, leptin influences neurons that 
directly or indirectly regulate levels of other 
circulating hormones (e.g. thyroid hormone, 
sex steroids, and GH) [9, 11]. ObRb is also ex-
pressed in multiple peripheral tissues, including 
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pancreatic islets, adipose tissue, skeletal mus-
cle, liver, and immune cells [12, 13]. In the 
pancreatic islets, leptin directly inhibits insulin 
expression and secretion [14]. In liver and white 
adipose tissue, leptin inhibits lipogenesis and 
stimulates lipolysis [12, 13]. Leptin directly pro-
motes fatty acid oxidation in isolated adipocytes 
and skeletal muscle [10, 15] and decreases lipid 
levels in isolated livers [16]. 
Leptin takes part in the regulation of en-
ergy homeostasis, insulin action and lipid me-
tabolism [1] by improving insulin sensitivity and 
reducing intracellular lipids [17–19].
The ability of leptin to inhibit feeding is re-
lated to activation of PI3 kinase in the hypo-
thalamus. Blockade of PI3 kinase activity pre-
vents the anorectic action of leptin [20].
Congenital leptin deficiency is associated 
with hyperphagia, impaired thermogenesis, 
insulin resistance, hyperlipidemia, and central 
hypogonadism, which can be reversed by leptin 
treatment [20, 21].
Women have higher leptin concentrations 
than men. But after menopause a significant 
reduction in the amount of circulating leptin 
occurs [22]. Such sexual differences can be 
explained by the difference in fat mass, body 
fat distribution, and sex hormones. Leptin 
level is also independent of body mass index. 
Subcutaneous fat expresses more leptin mRNA 
than omental (visceral) fat, and this may par-
tially contribute to increased leptin levels in 
women compared with men [23]. 
Deficient leptin signaling results in hyper-
phagia and decreased energy expenditure [24]. 
The result is not only an increasing degree of 
obesity associated with increased lipid storage 
in muscle, liver, and other tissues but also dys-
function of several neuroendocrine axes, in-
cluding the reproductive, thyroid, and adrenal 
axes, as well as abnormal function of the im-
mune and autonomic system (i.e. thermoregu-
lation, energy expenditure, and others) [17,24].
Normally leptin reduces along with insulin 
during fasting and mediates the suppression 
of thyroid hormone, growth hormone and re-
productive hormones. Leptin causes stimula-
tion of appetite and inhibition of sympathetic 
nerve activity [25, 26].
Chronic weight loss in females and obese 
patients on dietary restriction decreases leptin, 
resulting in suppression of reproductive hor-
mones, disruption of menstrual cycles, and 
energy use by muscle [27, 28].
Leptin may control glucose homeostasis 
independently of its effects on adiposity [29]. 
It regulates glycaemia via the CNS, but it may 
also directly regulate the physiology of pancre-
atic β-cells [30, 31] and peripheral insulin-sen-
sitive tissues [32]. It was also proved that leptin 
acting through LRb regulates insulin receptor 
substrate-1 and 2, mitogen-activated protein 
kinase, extracellular signal-regulated kinase, Akt, 
and PI3 kinase, raising the possibility of inter-
action between leptin and insulin [33]. Anti-
diabetic properties of leptin as a suppressor of 
glucagon are shown in some literature [34–36].
Leptin also limits accumulation of triglycer-
ides in liver and skeletal muscle through a 
combination of direct activation of AMPK and 
indirect actions mediated through central neu-
ral pathways, thereby improving insulin sensi-
tivity [37]. Attenuation of leptin sensitivity in 
brain leads to excess triglyceride accumulation 
in adipose tissue, as well as muscle, liver, and 
pancreas, resulting in impaired insulin sensitiv-
ity and secretion [38].
Although obese subjects are hyperleptine-
mic compared with thin persons [39], they ap-
pear either to be tolerant or resistant to the 
central hypothalamic effects of leptin. The re-
duced sensitivity toward exogenous and en-
dogenous leptin is commonly referred to as 
leptin resistance [40]. However, leptin is not 
widely used in the clinical field because obesity 
is accompanied by increased serum leptin and 
responds poorly to the pharmacological admin-
istration of exogenous leptin, which ordinarily 
potently promotes fat mass loss and body 
weight reduction in thin subjects [41, 42].
Fig. 1. Leptin structure [81]. 
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Alterations in the signaling of the long iso-
form of the leptin receptor, especially in the 
hypothalamic arcuate nucleus, seem to play a 
crucial role in leptin resistance. Additional 
mechanisms that were proposed to induce 
resistance toward the effects of leptin include 
alterations in the transport of leptin across the 
blood-brain barrier. The protein tyrosine phos-
phatase 1B is another potential mechanism that 
was proposed to interfere with leptin signaling 
by inhibiting signaling of the long isoform of 
the leptin receptor [24, 43].
Leptin insensitivity and insulin resistance 
play a major role in the development of type 2 
diabetes [44]. It can be explained by high levels 
of insulin and leptin as well as with hyperphagia 
in patients with obesity [45].
Leptin resistance as a development fac-
tor of obesity and type 2 diabetes
The WHO has declared obesity as the lar gest 
global chronic health problem in adults, and it 
is considered the 5th leading risk for life globally 
[46]. Obesity is a ‘gateway’ for diabetes [47].
Worldwide, 415 million people have diabe-
tes, and this number will reach 642 million by 
2040 [48]. Type 2 diabetes accounts for 90-95% 
of all diabetes.
This form encompasses individuals who 
have relative (rather than absolute) insulin defi-
ciency and have peripheral insulin resistance 
[49]. Nearly 90% of individuals with type 2 dia-
betes are either overweight or obese [50]. Ex-
cess weight itself causes some degree of insu-
lin resistance. Patients with type 2 diabetes may 
have insulin levels that appear normal or in-
creased; the increased blood glucose levels in 
these patients would be expected to result in 
even higher insulin values and to have their 
b-cell function in norm. Thus, insulin secretion 
is defective in these patients and insufficient to 
compensate for insulin resistance [49].
Leptin resistance was introduced in an ap-
parent analogy with that of insulin resistance 
to explain why hyperleptinemia associated with 
obesity fails to correct the defect in energy bal-
ance and feeding behaviour [51]. In obesity, the 
transport of leptin across the blood brain bar-
rier is decreased and levels of suppressors of 
cytokine signaling-3 (SOCS-3), an inhibitor of 
leptin signaling is increased in hypothalamus, 
which leads to leptin resistance [52]. Therefore, 
the concept of ‘leptin resistance’ has been chal-
lenged recently by an alternate concept of 
‘hypothalamic leptin insufficiency’ [53].
It is assumed that leptin resistance contrib-
utes to hyperphagia [54, 55]. It is also possible 
that surfeit may induce leptin resistance and 
other metabolic sequelae of obesity [45]. This 
rapid adaptation to increased energy availabil-
ity may be designed to curtail the leptin system 
to facilitate storage of nutrients into lipid stores 
[54, 56]. This may be accomplished by restrain-
ing leptin biosynthesis [57–59] and/or by induc-
ing leptin resistance [54, 56]. These mecha-
nisms would be particularly well developed in 
individuals predisposed to weight gain and 
diabetes [54, 60]. Consistent with the ‘thrifty 
genotype’ hypothesis, this sequence of events 
would be tightly coupled to the onset of insulin 
resistance [45, 54]. 
Inadequate early increase in leptin secre-
tion and biosynthesis (Table 1) in response to 
overeating may also play a role in the develop-
ment of obesity and glucose intolerance [61].
Table 1. The scheme of metabolic disorders in the human body initiated by leptin resistance 
(based on the Fig. 2 by Kalra S.P., 2008)
Diminished leptin transport across blood–brain barrier
↓
Leptin resistance
↓
Hypothalamic leptin insufficiency with 
defections in hypothalamic regulation of energy homeostasis
↓
Decreased restraint on pancre-
atic insulin secretion
Decreased glucose metabolism in 
peripheral organs
Decreased energy expendi-
ture
                             ↓                                  ↓                                    ↓
Hyperinsulinemia with insulin 
resistance → Hyperglycemia with increased energy stores → Adipogenesis  and obesity
                 ↓
Hyperleptinemia 
metabolic syndrome 
type 2 diabetes
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Metformin action in patients with leptin 
resistance
Metformin remains the preferred first-line 
pharmacologic agent for the treatment of type 
2 diabetes [62]. the use of metformin as a first-
line therapy was supported by the findings of 
a large meta-analysis with selection of second-
line therapies based on patient-specific consid-
erations [63]. 
Metformin acts mainly by reducing hepatic 
glucose production via inhibition of gluconeo-
genesis [64, 65] and increases glucose uptake 
in peripheral tissue [65]. Metformin is associ-
ated with a low risk of hypoglycemia and is 
weight neutral or can lead to weight loss [66]. 
Moreover, metformin decreases leptin con-
centration in morbidly obese subjects [67, 68] 
and in normal-weight healthy men [69]. Al-
though leptin concentration is closely related 
to body fat mass, the leptin-reducing effect of 
metformin cannot be fully explained by body 
weight reduction because metformin reduces 
leptin level even without changing body weight 
in normal-weight healthy men [69].
It was proved that weight loss achieved by 
metformin was correlated with pre-treatment 
plasma leptin levels. This effect of metformin 
was paralleled by a stimulation of the expres-
sion of the leptin receptor gene (ObRb) in the 
arcuate nucleus. Thus, identifying the hypotha-
lamic ObRb as a gene was modulated after 
metformin treatment [70].
It has been recently reported that met-
formin targets the AMP-activated protein ki-
nase (AMPK), which is also activated by leptin 
[71–73].
Several researches have been performed 
to analyse the molecular mechanism behind 
the effect of metformin on leptin levels. An in-
vitro study reports that metformin inhibits 
leptin secretion by inhibiting MAPK signaling 
pathway in adipocytes [74].
The other studies has proved that met-
formin restores leptin sensitivity in obese rats 
with leptin resistance and metformin treatment 
increases cerebrospinal fluid leptin concentra-
tions in both standard chow and high fat-fed 
obese rats compared with the untreated rats. 
The authors have also reported that metform-
in increases hypothalamic POMC (an anorexi-
genic peptide) expression by leptin treatment 
in high fat-fed obese rats, whereas this is not 
observed in untreated high fat-fed obese rats 
[75].
As the effect of leptin is associated with the 
activation of POMC, failure to activate POMC 
expression by leptin is an evidence of leptin 
resistance [76].
Distinct reduction in serum leptin level was 
observed in non-obese healthy individual on 
metformin, without any reduction in body 
weight [77].
But some studies have shown poor relation-
ship between metformin action and leptin 
level [78, 79].
Although many researches have been con-
ducted, the mechanism of metformin action on 
leptin resistance remains unclear. Moreover, 
similar investigations have contrary outcomes. 
Therefore, this issue requires further research.
Conclusions
Leptin, the adipocyte-secreted hormone, 
has direct and indirect effects on metabolically 
active tissues, and regulates several neuroen-
docrine axes. It takes part in the regulation of 
energy homeostasis, insulin action and lipid 
metabolism, and signals primarily on the status 
of the body energy reserves in fat to brain and 
other tissues. Circulating leptin levels are di-
rectly proportional to the amount of body fat. 
Leptin concentration are increased in obesity 
and decreased during fasting. In obesity, the 
transport of leptin across the blood brain bar-
rier is diminished, which leads to leptin resist-
ance. Leptin insensitivity and insulin resistance 
play a major role in the development of type 2 
diabetes.
Metformin decreases both insulin and lep-
tin concentration, restores the sensitivity to 
these hormones.
But the mechanism of metformin action on 
leptin resistance remains unclear. The leptin-
reducing effect of metformin cannot be fully 
explained only by body weight reduction. Fur-
thermore, some studies have proved poor re-
lationship between metformin action and leptin 
level. All these aspects require an in-depth re-
search. 
Considering the topical matter of exploring 
metformin action due to polymorphisms in 
genes encoding drug receptors, transporters, 
and metabolizing enzymes [80], the study of 
the relationship between genetic variants in 
solute carrier transporters and changes in lep-
tin levels under metformin therapy would be 
reasonable. 
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